ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1658

IGF1 Drives Wnt-induced Joint Damage and Is a Therapeutic Target for Osteoarthritis

Ana Escribano-Nunez1, Frederique Cornelis2, Astrid Deroover1, An Sermon1, Frederic Cailotto3, Rik Lories2 and Silvia Monteagudo4, 1KU Leuven, Leuven, Vlaams-Brabant, Belgium, 2Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, 3Université Lorraine, Nancy, Lorraine, France, 4KU Leuven, Leuven, Belgium

Meeting: ACR Convergence 2024

Keywords: cartilage, Cartilage Degradation, chondrocyte, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: Osteoarthritis & Joint Biology – Basic Science

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Osteoarthritis is the most common joint disease and a global leading cause of pain and disability. Its multifactorial etiology includes excessive activation of Wnt signaling. However, how Wnt signaling causes joint destruction remains poorly understood.

Methods: We analysed two different genome-wide transcriptome datasets of articular cartilage with Wnt hyper-activation. First, a dataset from human articular chondrocytes (hACs) with inhibited DOT1L (GSE77916), a histone methyltransferase that restricts Wnt signaling in chondrocytes to maintain joint homeostasis. Second, a dataset from articular cartilage of mice with deletion in Frzb (GSE33656), a Wnt extracellular antagonist. We performed protein network analysis of differentially expressed genes using db-STRING and HumanBase tools. QPCR validated IGF1 expression changes, and in vivo IGF1 protein levels were measured using immunohistochemistry. We assessed the impact of direct Wnt signaling activation on IGF1 expression by treating hACs with WNT3A and GSK-3β inhibitors (CHIR-99021, lithium chloride) followed by qPCR and ELISA analysis. We generated cartilage-specific Igf1 KO (Igf1CART-KO) mice to functionally study the Wnt/IGF1 link. We investigated the transcriptional regulation of IGF1 by Wnt signaling using luciferase reporter assays and ChIP-qPCR. The translational impact of reducing Wnt-mediated IGF1 for osteoarthritis was evaluated in the DMM mouse model using Igf1CART-KO mice and in hACs from patients upon siRNA-mediated IGF1 silencing.

Results: Our unbiased bioinformatic analysis revealed transcriptional networks in the Wnt hyper-activation models triggered by DOT1Linhibition or Frzb KO with IGF1 as a prominent node, linking Wnt signaling and IGF1. Increased IGF1 expression was found in articular cartilage from Dot1l and Frzb KO mice. Direct Wnt activation with WNT3A or GSK-3β inhibitors in hACs led to concentration-dependent IGF1 upregulation, comparable to the direct Wnt target gene TCF1. Intra-articular treatment with Wnt activator CHIR-99021 in wild-type mice also increased IGF1 protein levels. Igf1CART-KO mice exhibited less cartilage damage and osteophyte formation upon Wnt hyper-activation with CHIR-99021, compared to controls. Additionally, cartilage-specific deletion of Igf1 prevented hypertrophic differentiation and aggrecan degradation in response to Wnt activation. Mechanistically, ChIP-qPCR demonstrated that IGF1 is a direct Wnt target gene, with Wnt transcription factor TCF4 acting as a positive regulator and TCF3 as a repressor in an orchestrated TCF switch mechanism. In the DMM model, Igf1CART-KO mice showed reduced cartilage damage, osteophyte formation, and chondrocyte hypertrophy. Silencing IGF1 in hACs from osteoarthritis patients restored a healthy molecular profile, increasing COL2A1 and ACAN expression while reducing MMP13 and ADAMTS4/5 levels.

Conclusion: These findings identify IGF1 as a key downstream player in Wnt signaling-driven joint damage and suggest therapeutic potential in targeting IGF1 for osteoarthritis treatment.


Disclosures: A. Escribano-Nunez: None; F. Cornelis: None; A. Deroover: None; A. Sermon: None; F. Cailotto: None; R. Lories: abbvie, 2, 6, biocon, 2, 6, Biosplice, 1, 2, 6, Eli Lilly, 2, 6, Novartis, 2, 6; S. Monteagudo: None.

To cite this abstract in AMA style:

Escribano-Nunez A, Cornelis F, Deroover A, Sermon A, Cailotto F, Lories R, Monteagudo S. IGF1 Drives Wnt-induced Joint Damage and Is a Therapeutic Target for Osteoarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/igf1-drives-wnt-induced-joint-damage-and-is-a-therapeutic-target-for-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/igf1-drives-wnt-induced-joint-damage-and-is-a-therapeutic-target-for-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology